| Myocardial Infarction
Brilinta vs Praluent
Side-by-side clinical, coverage, and cost comparison for myocardial infarction.Deep comparison between: Brilinta vs Praluent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPraluent has a higher rate of injection site reactions vs Brilinta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Praluent but not Brilinta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Brilinta
Praluent
At A Glance
Oral
Twice daily
P2Y12 platelet inhibitor
SC injection
Every 2-4 weeks
PCSK9 inhibitor
Indications
- Acute Coronary Syndrome
- Myocardial Infarction
- Coronary Artery Disease
- Acute Ischemic Stroke
- Transient Ischemic Attack
- Stent thrombosis
- Myocardial Infarction
- Coronary heart disease
- Cerebrovascular accident
- Angina, Unstable
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
Dosing
Acute Coronary Syndrome, Myocardial Infarction, Stent thrombosis 180 mg oral loading dose, then 90 mg twice daily for the first year; after one year, 60 mg twice daily; use with aspirin 75-100 mg daily.
Coronary Artery Disease 60 mg twice daily; use with aspirin 75-100 mg daily.
Acute Ischemic Stroke, Transient Ischemic Attack 180 mg loading dose, then 90 mg twice daily for up to 30 days; use with aspirin 300-325 mg loading dose and 75-100 mg daily maintenance.
Hypercholesterolemia, Myocardial Infarction, Coronary heart disease, Cerebrovascular accident, Angina, Unstable 75 mg SC once every 2 weeks or 300 mg SC once every 4 weeks; may adjust to 150 mg SC every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (adults on LDL apheresis), Homozygous Familial Hypercholesterolemia 150 mg SC once every 2 weeks; may be administered without regard to timing of LDL apheresis.
Familial hypercholesterolemia - heterozygous (pediatric, <50 kg) 150 mg SC once every 4 weeks; may adjust to 75 mg SC once every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (pediatric, >=50 kg) 300 mg SC once every 4 weeks; may adjust to 150 mg SC once every 2 weeks if LDL-C response is inadequate.
Contraindications
- History of intracranial hemorrhage
- Active pathological bleeding (e.g., peptic ulcer or intracranial hemorrhage)
- Hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product
- Previous serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT
Adverse Reactions
Most common (>=4%) Dyspnea, dizziness, nausea, bleeding
Serious Major bleeding, fatal/life-threatening bleeding, intracranial hemorrhage, bradycardia, ventricular pauses
Postmarketing Thrombotic Thrombocytopenic Purpura, hypersensitivity reactions including angioedema, central sleep apnea, Cheyne-Stokes respiration, rash
Most common (>=2%) Injection site reactions, influenza, diarrhea, myalgia, muscle spasms, contusion
Serious Hypersensitivity vasculitis, nummular eczema, angioedema
Postmarketing Angioedema, influenza-like illness
Pharmacology
P2Y12 platelet inhibitor; ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation, with ticagrelor and its active metabolite being approximately equipotent.
Alirocumab is a human monoclonal antibody that inhibits PCSK9, a protein that promotes LDL receptor degradation on hepatocytes, thereby increasing LDL receptor availability and lowering circulating LDL-C levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Brilinta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (3/12) · Qty limit (9/12)
Praluent
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Brilinta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (3/8)
Praluent
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Brilinta
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Praluent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Brilinta.
$50/momo
MyPraluent Copay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BrilintaView full Brilinta profile
PraluentView full Praluent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.